Literature DB >> 11923586

Metadoxine in acute alcohol intoxication: a double-blind, randomized, placebo-controlled study.

Leonid S Shpilenya1, Alexander P Muzychenko, Giovanni Gasbarrini, Giovanni Addolorato.   

Abstract

BACKGROUND: At present there are only intriguing and preliminary clinical results regarding the efficacy of metadoxine (pyridoxol L-2-pyrrolidone-5-carboxylate) in acute alcohol intoxication. The present study was planned with the aim of investigating the effectiveness of metadoxine in the management of patients affected by acute ethanol intoxication.
METHODS: A double-blind, randomized, multicenter, placebo-controlled trial was carried out on 58 patients of both sexes with acute ethanol intoxication. Patients were treated with a single dose of 900-mg intravenous metadoxine (n = 29) or with placebo (n = 29). Patients were clinically and biochemically evaluated at 0.5, 1, 2, 3, 6, 9, and 12 hr after treatment.
RESULTS: Treatment with metadoxine significantly decreased the half-life of ethanol in blood (from 6.70 +/- 1.84 to 5.41 +/- 1.99 hr; p < 0.013) and showed a faster rate of ethanol elimination. The effects on ethanol half-life in blood were accompanied by a faster onset of recovery from intoxication, defined as the time of the transition of blood ethanol levels to the immediately lower range defined by intoxication categories (in g/liter: 0 to 0.5, absent; 0.51 to 1.0, mild; 1.1 to 2.5, moderate; >2.5, severe). Thus the median time to onset of recovery was 0.95 hr with metadoxine and 2.34 hr with placebo (p = 0.013). The effects of treatment on blood alcohol levels were paralleled by a significant decrease in the rating of the toxic clinical symptomatology. At 2 hr the improvement of toxic symptoms (in percent of maximum possible) was 68 +/- 28 vs. 44 +/- 27% in controls (p < 0.002).
CONCLUSIONS: In patients with acute ethanol intoxication metadoxine accelerated the elimination of ethanol from blood, which led to faster recovery from intoxication, and improved the behavioral toxic symptomatology. Metadoxine could be helpful in the management of acute ethanol intoxication.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923586

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  9 in total

Review 1.  Altering ethanol pharmacokinetics to treat alcohol use disorder: Can you teach an old dog new tricks?

Authors:  Carolina L Haass-Koffler; Fatemeh Akhlaghi; Robert M Swift; Lorenzo Leggio
Journal:  J Psychopharmacol       Date:  2017-01-16       Impact factor: 4.153

Review 2.  Pharmacotherapy for alcohol use disorder: current and emerging therapies.

Authors:  Robert M Swift; Elizabeth R Aston
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

3.  Dihydromyricetin Protects Against Ethanol-Induced Toxicity in SH-SY5Y Cell Line: Role of GABAA Receptor.

Authors:  Bruk Getachew; Antonei B Csoka; Yousef Tizabi
Journal:  Neurotox Res       Date:  2022-04-07       Impact factor: 3.911

4.  Involvement of protein kinase C and Src tyrosine kinase in acute tolerance to ethanol inhibition of spinal NMDA-induced pressor responses in rats.

Authors:  W-K Hsieh; H-H Lin; C-C Lai
Journal:  Br J Pharmacol       Date:  2009-08-24       Impact factor: 8.739

5.  A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence.

Authors:  Irene Guerrini; Claudio Gentili; Gloria Nelli; Mario Guazzelli
Journal:  Subst Abuse Treat Prev Policy       Date:  2006-12-18

6.  Recurrent lactic acidosis secondary to hand sanitizer ingestion.

Authors:  M E Wilson; P K Guru; J G Park
Journal:  Indian J Nephrol       Date:  2015 Jan-Feb

7.  Rapid Elimination of Blood Alcohol Using Erythrocytes: Mathematical Modeling and In Vitro Study.

Authors:  Yuliya G Alexandrovich; Elena A Kosenko; Elena I Sinauridze; Sergey I Obydennyi; Igor I Kireev; Fazoil I Ataullakhanov; Yuriy G Kaminsky
Journal:  Biomed Res Int       Date:  2017-05-31       Impact factor: 3.411

8.  Emergence agitation after intraoperative neurolytic celiac plexus block with alcohol: a case report.

Authors:  Huixuan Zhou; Yinbing Pan; Cunming Liu; Xiaodi Sun
Journal:  BMC Anesthesiol       Date:  2021-08-16       Impact factor: 2.217

Review 9.  Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.

Authors:  James J Connolly; Kohtaro Ooka; Joseph K Lim
Journal:  J Clin Transl Hepatol       Date:  2018-06-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.